Progress in Medicinal Chemistry - 1st Edition - ISBN: 9780123964939, 9780444594426

Progress in Medicinal Chemistry, Volume 51

1st Edition

Serial Editors: G. Lawton David R. Witty
Hardcover ISBN: 9780123964939
eBook ISBN: 9780444594426
Imprint: Elsevier
Published Date: 1st May 2012
Page Count: 160
Tax/VAT will be calculated at check-out
148.00
195.00
119.00
195.41
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

  1. Small Molecule Bromodomain Inhibitors: Extending the Druggable Epigenome
  2. Chun-wa Chung

  3. TRPV1 Antagonists: Clinical Setbacks and Prospects for Future Development
  4. Michael E. Kort and Philip R. Kym

  5. Multivalent Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) Molecules for the Treatment of COPD
  6. Adam D. Hughes, Alexander McNamara and Tod Steinfeld

  7. Hematopoietic Prostaglandin D-Synthase Inhibitors

    Sukanthini Thurairatnam

Description

Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

Key Features

  • Progress in Medicinal Chemistry provides a review of eclectic developments in medicinal chemistry

Readership

Chemists, biologists, doctors, pharmacists and anyone interested in the contemporary controversy about drugs, drug firms, and the community


Details

No. of pages:
160
Language:
English
Copyright:
© Elsevier 2012
Published:
Imprint:
Elsevier
eBook ISBN:
9780444594426
Hardcover ISBN:
9780123964939

About the Serial Editors

G. Lawton Serial Editor

Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business.

From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines.

Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities.

Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs.

He is a founder of INMedD, a new medicines discovery social enterprise.

Affiliations and Expertise

St. Ippolyts, Herts, UK

David R. Witty Serial Editor

Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and Expertise

Convergence Pharmaceuticals Ltd, Cambridge, UK